Condition
Tolerability clinical trials and research
As of November 12, 2026, Find a Trial lists 7 Tolerability clinical trials that are recruiting, at sites in 2 countries (most in China (6), Germany (1)). By phase: Phase 1 (5), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 2Countries
Newest Tolerability clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| GenSci142 as a vaginal treatment for bacterial vaginosis | Phase 1 | Beijing, Beijing Municipality and 8 other locations | Recruiting | Jun 23, 2026 |
| GenSci098 for adults with Graves' disease | Phase 1 | Shenyang, Liaoning | Recruiting | Dec 16, 2025 |
| GenSci134 in healthy adults and adults with growth hormone deficiency | Phase 1 | Beijing, Beijing Municipality | Recruiting | Jun 12, 2025 |
| Evaluating the safety and tolerability of RCS-21 in healthy volunteers | Phase 1 | Hanover | Recruiting | Dec 30, 2024 |
| Evaluating HY07121 for patients with advanced solid tumors | Phase 1/2 | Jinan | Recruiting | Oct 15, 2024 |
| Evaluating GenSci098 for treating active thyroid eye disease | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Aug 26, 2024 |
| Testing HYP-2090PTSA in patients with advanced solid tumors and KRAS mutations | Phase 1/2 | Fuzhou, Fujian and 5 other locations | Recruiting | Feb 6, 2024 |
All recruiting trials (7)
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
-
GenSci098 for adults with Graves' disease
This phase 1 trial will test single increasing subcutaneous doses of GenSci098 to see if they are safe and well tolerated in adults with Graves' disease.
-
GenSci134 in healthy adults and adults with growth hormone deficiency
This Phase 1 trial will test single and multiple subcutaneous doses of GenSci134 in healthy adults and single doses in adults with growth hormone deficiency to check safety, tolerability, pharmacokinetics, pharmacodynamics, and immune response.
-
Evaluating the safety and tolerability of RCS-21 in healthy volunteers
This study is testing a new inhaled medication called RCS-21 to see how safe it is and how well it works in healthy volunteers.
-
Evaluating HY07121 for patients with advanced solid tumors
This study is testing a new drug called HY07121 to see if it is safe and effective for people with advanced solid tumors.
-
Evaluating GenSci098 for treating active thyroid eye disease
This study is testing a new treatment called GenSci098 to see if it is safe and helpful for people with active thyroid eye disease linked to Graves' disease.
-
Testing HYP-2090PTSA in patients with advanced solid tumors and KRAS mutations
This study is testing a new drug called HYP-2090PTSA to see if it can safely help people with advanced solid tumors that have a KRAS mutation.
Related topics
Quick answers
How many Tolerability clinical trials are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (6 trials), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 5, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.